AbbVie is successfully weathering the 2023 loss of exclusivity for its mega-blockbuster Humira. The company is projecting accelerated growth, driven by the strong performance of its newer immunology drugs, SKYRIZI and REVOK, showcasing a best-in-class lifecycle management strategy.
Widespread conservative 2026 guidance across biopharma is not driven by anticipated tariffs or policy changes. Instead, companies are finally feeling the direct impact of the long-discussed "patent cliff," with multiple major firms citing imminent losses of exclusivity (LOEs) for their blockbuster drugs as the primary headwind.
Despite facing major patent expirations, Johnson & Johnson is projecting growth and is on track to surpass $100 billion in revenue. This success is largely attributed to its strategic spinoff of the consumer health unit, Kenvue, which allowed for greater focus and stronger performance within its core pharmaceutical business.
Eli Lilly’s astronomical growth is also a forecasting challenge. The company significantly undershot its own sales projections, with its CEO admitting the obesity market is a unique "learning experience." This highlights that demand for GLP-1 drugs represents not just market capture, but the creation of an entirely new, rapidly expanding, and unpredictable market.
In an ironic turn, generics manufacturer Teva is projecting a 4% revenue decrease after several years of growth. The primary cause is not new competition, but an expected sales drop of $1.1 billion from its own generic version of the cancer drug Revlimid, illustrating the volatility even within the high-value generics market.